dupilumab
FDA Approves Dupixent for Pediatric Eosinophilic Esophagitis
The FDA approved Dupixent to treat eosinophilic esophagitis in children ages 1 year and older.
JANUARY 26, 2024
FDA Grants Dupixent a New Indication for Prurigo Nodularis
The FDA granted a new indication for Dupixent to treat adults with prurigo nodularis.
SEPTEMBER 29, 2022
FDA Expands Dupilumab Indication to EoE
Dupilumab is now indicated for the treatment eosinophilic esophagitis in patients 12 years and older weighing more ...
MAY 23, 2022
Atopic Dermatitis in the Specialty World
Therapy for atopic dermatitis (AD), a chronic inflammatory skin disease that usually starts in infancy or early ...
AUGUST 12, 2019
FDA Approves First Treatment for Chronic Rhinosinusitis With Nasal Polyps
The FDA granted a new indication for Dupixent to treat adults with nasal polyps accompanied by chronic ...
JUNE 27, 2019
Dupixent Appears to Increase Asthma Control Among Poorly Controlled Patients
When added to standard therapies, Dupixent reduced severe asthma exacerbations and improved lung function in a ...
SEPTEMBER 22, 2017
